Lyell Immunopharma (NASDAQ:LYEL) Earns Neutral Rating from HC Wainwright

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $1.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 70.82% from the stock’s current price.

Lyell Immunopharma Stock Performance

NASDAQ LYEL opened at $0.59 on Thursday. The firm has a 50 day simple moving average of $0.62 and a 200-day simple moving average of $0.92. Lyell Immunopharma has a one year low of $0.51 and a one year high of $3.15. The firm has a market cap of $171.03 million, a price-to-earnings ratio of -0.74 and a beta of -0.41.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The business had revenue of $0.01 million during the quarter. Equities analysts predict that Lyell Immunopharma will post -0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Barclays PLC lifted its stake in Lyell Immunopharma by 312.7% in the third quarter. Barclays PLC now owns 240,615 shares of the company’s stock worth $332,000 after acquiring an additional 182,315 shares during the last quarter. SG Americas Securities LLC lifted its stake in Lyell Immunopharma by 102.8% in the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company’s stock worth $75,000 after acquiring an additional 59,182 shares during the last quarter. Jane Street Group LLC lifted its stake in Lyell Immunopharma by 63.7% in the third quarter. Jane Street Group LLC now owns 287,717 shares of the company’s stock worth $397,000 after acquiring an additional 111,917 shares during the last quarter. State Street Corp lifted its stake in Lyell Immunopharma by 1.9% in the third quarter. State Street Corp now owns 3,889,553 shares of the company’s stock worth $5,368,000 after acquiring an additional 71,233 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in Lyell Immunopharma in the third quarter worth approximately $52,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.